While no effect on tumor growth was observed for the anti-PD-1 group alone, statistically significant inhibition of tumor growth was observed for all other treatment groups including the isotype Th-227 conjugate dosed at 500 kBq/kg with no apparent synergy for either PD-L1 TTC or isotype Th-227 conjugate with addition of the check point inhibitor (Figure 4). The gene discussed is CD274; the disease is neoplasm.